|Rapid Review Complete
|For the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine.
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|Full pharmacoeconomic assessment recommended at the submitted price.
The HSE has approved reimbursement following confidential price negotiations. January 2016.